Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Director | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tectonic Therapeutic, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2033-06-05 | Direct | 17,643 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,643 · Balance 17,643 F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 06, 2023 Filed Jun 8, 2023 16:31 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,643 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001127602-23-018296 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,643 Underlying: Common Stock · 17,643 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 6, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:45 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017247 · form4.xml · derivative · entry 2 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:45 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,478 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001127602-22-017247 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,478 Underlying: Common Stock · 17,478 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 8, 2023 or the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:34 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 17,438 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019818 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,438 Underlying: Common Stock · 17,438 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 10, 2022 or the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 17:06 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $21.91 | $0.00 |
DisclosureSEC source: 0001127602-20-019012 · form4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 4, 2021 or the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 21:26 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 15,000 | $28.00 | $420,000.00 |
DisclosureSEC source: 0000899243-20-004181 · doc4.xml · nonDerivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,512 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 28, 2020 Filed Jan 30, 2020 16:10 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 10,000 | $23.00 | $230,000.00 |
DisclosureSEC source: 0000899243-20-002356 · doc4.xml · nonDerivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,512 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 17:12 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 9,675 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0000899243-19-016858 · doc4.xml · derivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option shall vest in full upon the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the reporting person's continued service as a director through such vesting date. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 16:39 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 100 | $26.92 | $2,692.00 |
DisclosureSEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 4 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,512 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 08, 2019 Filed Apr 9, 2019 16:39 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 2,400 | $25.84 | $62,021.28 |
DisclosureSEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 3 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,612 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 to $26.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 16:39 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 867 | $26.21 | $22,723.81 |
DisclosureSEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 2 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,012 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 16:39 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | SaleCommon Stock | 6,633 | $25.59 | $169,759.03 |
DisclosureSEC source: 0000899243-19-010377 · doc4.xml · nonDerivative · entry 1 PAIGE CHRISTOPHER · CIK 0001742209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,879 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.975 , inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.